You just read:

Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012

News provided by

Argos Therapeutics Inc.

Apr 24, 2012, 08:00 ET